NCT07381894 Multicentre Hypertrophic Cardiomyopathy Registry
| NCT ID | NCT07381894 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Manchester |
| Condition | Hypertrophic Cardiomyopathy (HCM) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2029-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2026-04-01 with a primary completion date of 2029-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow tract obstruction), shortness of breath, and an increased risk of heart failure or sudden cardiac arrest. While standard treatments exist and new targeted medications (cardiac myosin inhibitors) have recently been approved, doctors still need better data to predict which treatments will work best for each individual patient. This national registry based in the UK is a secure database that collects health information from HCM patients across multiple NHS hospital sites in the UK over several years. Participants in this study will have their routine health information collected from their medical records, including details from heart scans (echocardiograms and MRIs), blood tests, and genetic information. With this HCM registry, we aim to improve disease understanding and risk prediction, paving the way for more personalised treatment plans for the HCM community in the future
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of Hypertrophic Cardiomyopathy (HCM) clinically and not solely explained by abnormal loading conditions (e.g., significant hypertension, valvular disease Exclusion Criteria: * Participants who do not fulfil the imaging and clinical diagnostic criteria of HCM
Frequently Asked Questions
Who can join the NCT07381894 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Hypertrophic Cardiomyopathy (HCM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07381894 currently recruiting?
Yes, NCT07381894 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Manchester to inquire about joining.
Where is the NCT07381894 trial being conducted?
This trial is being conducted at Manchester, United Kingdom.
Who is sponsoring the NCT07381894 clinical trial?
NCT07381894 is sponsored by University of Manchester. The trial plans to enroll 2,500 participants.